You are here

Article Text

Article menu
Download PDFPDF
Short report
Topiramate, nutrition and weight change: a prospective study
  1. K M Klein1,
  2. F Theisen2,
  3. S Knake1,
  4. W H Oertel1,
  5. J Hebebrand3,
  6. F Rosenow1,
  7. H M Hamer1
  1. 1
    Interdisciplinary Epilepsy-Centre, Department of Neurology, Philipps University, Marburg, Germany
  2. 2
    Interdisciplinary Epilepsy-Centre, Department of Child and Adolescent Psychiatry, Philipps University, Marburg, Germany
  3. 3
    Department of Child and Adolescent Psychiatry, University Duisburg-Essen, Germany
  1. Dr K M Klein, Interdisciplinary Epilepsy-Centre, Department of Neurology, Philipps-University Marburg, Rudolf-Bultmann-Str 8, 35033 Marburg, Germany; klein.km{at}staff.uni-marburg.de

Abstract

Purpose: To evaluate prospectively the relationship between appetite, food composition, nutritional habits and weight loss following administration of topiramate (TPM) and to identify predictors for TPM induced weight loss.

Methods: 22 patients with epilepsy who were started on TPM were prospectively followed for 6 months and contacted again after a mean follow-up time of 37.1 months.

Results: Body mass index (BMI) loss occurred in 59% of patients, with a mean weight loss of 9.5 kg after 6 months while receiving TPM without further weight loss at the long term follow-up. Weight loss was associated with reduction in appetite without affecting food composition. Predictors for BMI loss after 6 months were high initial BMI and body fat. After 3 weeks of treatment with TPM, the recorded parameters did not predict BMI loss but at 3 months, weight loss, reduction of appetite and amount of food intake were predictive for the amount of BMI loss after 6 months.

https://doi.org/10.1136/jnnp.2007.136929

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Funding: This study was supported by the “Bundesministerium für Bildung und Forschung” (National Genome Research Net 01GS0118) and by the EPICURE project (European Commission project within the Sixth Framework Programme, thematic priority Life Sciences, Genomics and Biotechnology for Health, contract No LSHM-CT-2006-037315). The sponsors were not involved in the study design, in the collection, analysis or interpretation of data, in the writing of the report or in the decision to submit the paper for publication.

    • Competing interests: FR and HMH received honoraria and FR also received research grants from Janssen-Cilag GmbH. This company markets topiramate in Germany.

    • Ethics approval: The study was approved by the local ethics committee.